First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, ...
The latest update is out from Werewolf Therapeutics ( (HOWL)). On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER ...
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking ...
Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback